MCID: CRN174
MIFTS: 20

Coronary Heart Disease 2 malady

Categories: Genetic diseases

Aliases & Classifications for Coronary Heart Disease 2

Aliases & Descriptions for Coronary Heart Disease 2:

Name: Coronary Heart Disease 2 54
Coronary Heart Disease, Susceptibility to, 2 13

Classifications:



External Ids:

OMIM 54 608316

Summaries for Coronary Heart Disease 2

MalaCards based summary : Coronary Heart Disease 2, also known as coronary heart disease, susceptibility to, 2, is related to hypomyelination with brainstem and spinal cord involvement and leg spasticity. An important gene associated with Coronary Heart Disease 2 is CHDS2 (Coronary Heart Disease, Susceptibility To, 2). The drugs Chlorhexidine and Everolimus have been mentioned in the context of this disorder. Affiliated tissues include heart.

Description from OMIM: 608316

Related Diseases for Coronary Heart Disease 2

Diseases in the Coronary Heart Disease 6 family:

Coronary Heart Disease 2 Coronary Heart Disease 5
Coronary Heart Disease 7 Coronary Heart Disease 9
Coronary Heart Disease 8 Coronary Heart Disease 4
Coronary Heart Disease 3

Diseases related to Coronary Heart Disease 2 via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 hypomyelination with brainstem and spinal cord involvement and leg spasticity 9.8 CHDS2 SOD1

Symptoms & Phenotypes for Coronary Heart Disease 2

Clinical features from OMIM:

608316

Drugs & Therapeutics for Coronary Heart Disease 2

Drugs for Coronary Heart Disease 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1046)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Chlorhexidine Approved, Vet_approved Phase 4,Phase 2,Phase 3 55-56-1 9552079 2713
2
Everolimus Approved Phase 4,Phase 2,Phase 3,Phase 1 159351-69-6 6442177
3
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 22916-47-8 4189
4
Sirolimus Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 53123-88-9 5284616 6436030 46835353
5
Insulin Glargine Approved Phase 4,Phase 3 160337-95-1
6
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 657-24-9 14219 4091
7
Zinc Approved Phase 4,Phase 3,Phase 2,Phase 1 7440-66-6 32051 23994
8
Ticagrelor Approved Phase 4,Phase 3,Phase 2,Phase 1 274693-27-5 9871419
9
Aspirin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 50-78-2 2244
10
Cilostazol Approved Phase 4,Phase 3,Phase 2 73963-72-1 2754
11
Ticlopidine Approved Phase 4,Phase 2,Phase 3,Phase 1 55142-85-3 5472
12
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 3 73590-58-6 4594
13
Pantoprazole Approved Phase 4,Phase 3 102625-70-7 4679
14
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2 111025-46-8 4829
15
Simvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1 79902-63-9 54454
16
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 33069-62-4 36314
17
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 64-17-5 702
18
Rosiglitazone Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 122320-73-4 77999
19
Bivalirudin Approved, Investigational Phase 4,Phase 3,Phase 2 128270-60-0 16129704
20
Eptifibatide Approved, Investigational Phase 4,Phase 3,Phase 2 188627-80-7 123610
21
Amlodipine Approved Phase 4,Phase 3,Phase 2 88150-42-9 2162
22
Adenosine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-61-7 60961
23
Nicorandil Approved Phase 4,Phase 3 65141-46-0 47528
24
Olmesartan Approved, Investigational Phase 4,Phase 3,Phase 2 144689-24-7, 144689-63-4 158781 130881
25
Pravastatin Approved Phase 4,Phase 3,Phase 2,Phase 1 81093-37-0 54687
26
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 9005-49-6 772 46507594
27
Udenafil Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 268203-93-6 6918523
28
Ranolazine Approved, Investigational Phase 4,Phase 2,Phase 3 142387-99-3, 95635-55-5 56959
29
Cyproterone Acetate Approved, Investigational Phase 4 427-51-0
30
Ethinyl Estradiol Approved Phase 4,Phase 1 57-63-6 5991
31
Tirofiban Approved Phase 4,Phase 3,Phase 2,Phase 1 144494-65-5 60947
32
Esomeprazole Approved, Investigational Phase 4,Phase 2 161796-78-7, 119141-88-7 4594 9579578
33
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
34
Citalopram Approved Phase 4,Phase 2,Phase 3,Phase 1 59729-33-8 2771
35
Metoprolol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 37350-58-6, 51384-51-1 4171
36
Bisoprolol Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 66722-44-9 2405
37
Candesartan Approved Phase 4,Phase 3,Phase 2 139481-59-7 2541
38
Diltiazem Approved Phase 4,Phase 3,Phase 1 42399-41-7 39186
39
Amiodarone Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1 1951-25-3 2157
40
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1994-09-7, 94-09-7 2337
41
Menthol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 2216-51-5 16666
42
Rivaroxaban Approved Phase 4,Phase 3,Phase 2 366789-02-8
43
Warfarin Approved Phase 4,Phase 2,Phase 3 81-81-2 6691 54678486
44
Clonidine Approved Phase 4 4205-90-7 2803
45
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 50-28-2 5757 53477783
46
Progesterone Approved, Vet_approved Phase 4,Phase 2 57-83-0 5994
47
Abciximab Approved Phase 4,Phase 3,Phase 2 143653-53-6
48
Carvedilol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 72956-09-3 2585
49
Verapamil Approved Phase 4,Phase 2,Phase 3 52-53-9 2520
50
Dipyridamole Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-32-2 3108

Interventional clinical trials:

(show top 50) (show all 5000)
id Name Status NCT ID Phase
1 Firebird 2 Versus Excel Sirolimus-eluting Stent in Treating Real-world Patients With Coronary Artery Disease Unknown status NCT01373632 Phase 4
2 Can Insulin Glargine Improve Myocardial Function in Patients With T2D and Coronary Artery Disease (CAD) Unknown status NCT01035528 Phase 4
3 Pharmacodynamic Comparison of Rosuvastatin Versus Atorvastatin on Platelet Reactivity in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With New P2Y12 Inhibitors (Trial gRANADa) Unknown status NCT02030054 Phase 4
4 Efficacy and Safety of Firebird 2 Stent in Treatment of Complex Coronary Lesions in Diabetes Unknown status NCT01257373 Phase 4
5 Potential Impact of Cigarette Smoking on Platelet Reactivity in Patients on Dual Antiplatelet Therapy With P2Y12 Inhibitors Unknown status NCT02026713 Phase 4
6 Study Effects of Ginkgo Biloba Extract on Endothelial Cell Function and Genetic Effects on the Response to Ginkgo Biloba Extract in Diabetic Patients With Stable Coronary Artery Disease Unknown status NCT01038050 Phase 4
7 Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - SAfety & EffectiveneSS of Drug-ElUting Stents & Anti-platelet REgimen Unknown status NCT01267734 Phase 4
8 Comparative Phase IV Study: Efficacy And Safety of TiTAN2 Versus COBALT-CHROME Stents- EVIDENCEII Unknown status NCT01918150 Phase 4
9 Prevalence of Macrovascular Disease in Type 2 Diabetes Mellitus Unknown status NCT00298844 Phase 4
10 "Pharmacodynamic Comparison of Omeprazole Versus Pantoprazole on Platelet Reactivity in Patients With Acute Coronary Syndromes on Dual Antiplatelet Therapy With New P2Y12 Inhibitors" -Trial dOPPLER- Unknown status NCT02028234 Phase 4
11 A Prospective Multicenter Trial Evaluating Helios Biodegradable Polymer SES Safety and Effectiveness in CAD Treatment Unknown status NCT01880879 Phase 4
12 A Trial to Evaluate Efficacy of Heart-protecting Musk Pill Unknown status NCT01897805 Phase 4
13 Treatment of Coronary Atherosclerosis by Insulin Sensitizers in Insulin-Resistant Patients Unknown status NCT00155350 Phase 4
14 In Vitro and In Vivo Comparison Between Intravascular Ultrasound (IVUS) Systems Unknown status NCT02154295 Phase 4
15 Cerebral Artery Stenosis, Coronary Artery Disease and Arrhythmia Unknown status NCT00247533 Phase 4
16 Endothelial Dysfunction in Subjects With History of Premature Coronary Artery Disease Unknown status NCT00917527 Phase 4
17 Registry to Evaluate the Efficacy of Zotarolimus-Eluting Stent Unknown status NCT00960908 Phase 4
18 Trial to Assess the Everolimus-Eluting Coronary Stent System (PROMUS Element) for Coronary Revascularization Unknown status NCT01342822 Phase 4
19 Assessment of Stent Malapposition and Neointimal Coverage on Optical coHerence Tomography at Post-procedure and 3 Months After Platinum Chromium Alloy Of the Element™ Stent Implantation Unknown status NCT01581515 Phase 4
20 Revascularization in Heart Failure Trial – REHEAT 2 Unknown status NCT00388245 Phase 4
21 Low-dose Statins and Nutraceuticals in High-intensity Statin-intolerant Patients Unknown status NCT02001883 Phase 4
22 Overcoming High On-Treatment Platelet Reactivity (HPR) During Prasugrel Therapy With Ticagrelor Unknown status NCT01869309 Phase 4
23 Test Efficacy of Biodegradable and Permanent Limus-Eluting Stents Unknown status NCT01068106 Phase 4
24 The Beneficial Role of Percutaneous Coronary Intervention Over Optimal Medical Therapy in Elderly Patients With Coronary Artery Disease Unknown status NCT01508663 Phase 4
25 Assessment of Surface Coverage of Two Types of DES in Diabetes Mellitus and Non- Diabetes Mellitus Unknown status NCT01023919 Phase 4
26 Effect of Modifying Anti-platelet Treatment to Ticagrelor in Patients With Diabetes and Low Response to Clopidogrel Unknown status NCT01643031 Phase 4
27 Do Cobalt Chrome Stent and Paclitaxel-Eluting Stent Have Equivalent Clinical Result in Non-Complex Lesion? Unknown status NCT00852215 Phase 4
28 Intimal Hyperplasia Evaluated by Optical Coherence Tomography (OCT) in de Novo Coronary Lesions Treated by Drug-eluting Balloon and Bare-metal Stent Unknown status NCT01057563 Phase 4
29 Impact of Intravascular Ultrasound(IVUS)-Guided Chronic Total Occlusion Intervention With Drug-eluting Stents Unknown status NCT01563952 Phase 4
30 Randomized Trial of Creatine-kinase Leak After Rosuvastatin At the Time of Percutaneous Coronary Intervention Unknown status NCT01968577 Phase 4
31 Non-Polymer-Based, Rapamycin-Eluting Stents to Prevent Restenosis Unknown status NCT00152308 Phase 4
32 Rosiglitazone Therapy In The Prevention Of Coronary Artery Disease In Patients With Impaired Glucose Tolerance Unknown status NCT00733174 Phase 4
33 Peri-Procedural Myocardial Infarction, Platelet Reactivity, Thrombin Generation, and Clot Strength: Differential Effects of Eptifibatide + Bivalirudin Versus Bivalirudin Unknown status NCT00370045 Phase 4
34 Pharmacodynamic Effects of Atorvastatin vs. Rosuvastatin on Platelet Reactivity Unknown status NCT01567774 Phase 4
35 Comparison of Hyperemic Efficacy Between Nicorandil and Adenosine for Fractional Flow Reserve (FFR) Measurement Unknown status NCT01331902 Phase 4
36 Cilostazol Versus Aspirin for Primary Prevention of Atherosclerotic Events Unknown status NCT00886574 Phase 4
37 Test of Long-Term Safety and Efficacy of Sirolimus-Permanent-Polymer Eluting Stent (Cypher)- and Sirolimus-Polymer-free Eluting Stents (PPS/PFS) Assessed by Optical Coherence Tomography Unknown status NCT01260558 Phase 4
38 Test Safety and Efficacy of Zotarolimus- and Everolimus-Eluting Stents (ZES/EES) Assessed by Optical Coherence Tomography Unknown status NCT01230723 Phase 4
39 Platelet Function Assessment for Atherothrombotic Patients Unknown status NCT00513149 Phase 4
40 Vitamin K2 and Vessel Calcification in Chronic Kidney Disease Patients Unknown status NCT01101698 Phase 4
41 Diagnostic Benefits of HyperQTM vs. Conventional ECG Stress Test. Comparison of HyperQ vs. Stress ECG in Women Before Angiography Unknown status NCT00850486 Phase 4
42 Comparison of the Everolimus Eluting With the Biolimus A9 Eluting Stent Unknown status NCT01233453 Phase 4
43 Prospective Randomized Trial On RadiaTion Dose Estimates Of CT AngIOgraphy In PatieNts Scanned With A 100kV Protocol Unknown status NCT00611780 Phase 4
44 Prospective Randomized Trial On RadiaTion Dose Estimates Of CT AngIOgraphy In PatieNts Scanned With A Sequential Scan Protocol Unknown status NCT00612092 Phase 4
45 Comparison of Biolimus A9 and Everolimus Drug-Eluting Stents in Patients With ST Segment Elevation Myocardial Infarction Unknown status NCT00888758 Phase 4
46 Efficacy Study of Olmesartan Medoxomil on Coronary Atherosclerosis and Epicardial Adipose Tissue(EAT) Unknown status NCT02360956 Phase 4
47 The Effects of Pravastatin and Rosuvastatin on Coronary Plaques in Patients With Stable Angina Pectoris Unknown status NCT01325818 Phase 4
48 Cost-effectiveness of Genotype Guided Treatment With Antiplatelet Drugs in STEMI Patients: Optimization of Treatment Unknown status NCT01761786 Phase 4
49 Comparing Bivalirudin Versus Heparin/ GP IIB/IIA in Patients Undergoing PCI Unknown status NCT00476944 Phase 4
50 Zotarolimus and Everolimus-Eluting Stents ProsPectively Compared in Real World Unknown status NCT00768846 Phase 4

Search NIH Clinical Center for Coronary Heart Disease 2

Genetic Tests for Coronary Heart Disease 2

Anatomical Context for Coronary Heart Disease 2

MalaCards organs/tissues related to Coronary Heart Disease 2:

39
Heart

Publications for Coronary Heart Disease 2

Variations for Coronary Heart Disease 2

Expression for Coronary Heart Disease 2

Search GEO for disease gene expression data for Coronary Heart Disease 2.

Pathways for Coronary Heart Disease 2

GO Terms for Coronary Heart Disease 2

Sources for Coronary Heart Disease 2

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....